Otonomy, Inc. (NASDAQ:OTIC) Files An 8-K Other Events
Item 8.01 Other Events.
On April 9, 2020, Otonomy, Inc. (the “Company”) issued a press release providing a business update related to the novel coronavirus (COVID-19) pandemic. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
OTONOMY, INC. Exhibit
EX-99.1 2 otic-ex991_6.htm EX-99.1 otic-ex991_6.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Otonomy Provides Business Update Related to COVID-19 Pandemic SAN DIEGO,…
To view the full exhibit click here
About Otonomy, Inc. (NASDAQ:OTIC)
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.
